ArticleImmunotherapy2024
Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer.
Lin Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it